^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-15 stimulant

    Related drugs:
    22d
    A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Nkarta, Inc. | Phase classification: P1 --> P1/2 | N=48 --> 96
    Phase classification • Enrollment change
    |
    cyclophosphamide • fludarabine IV • NKX019
    1m
    INTERCEPT: Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Seattle Children's Hospital
    New P1 trial
    1m
    A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Nkarta, Inc. | Phase classification: P1 --> P1/2 | N=72 --> 144
    Phase classification • Enrollment change
    |
    cyclophosphamide • fludarabine IV • NKX019
    3ms
    Agni-01: Safety and Efficacy of OBX-115 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Obsidian Therapeutics, Inc. | Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2025 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • OBX-115
    4ms
    Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (clinicaltrials.gov)
    P1, N=21, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3-CAR and IL15 plus IL21
    6ms
    NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1) (clinicaltrials.gov)
    P1, N=48, Recruiting, Nkarta, Inc. | N=21 --> 48
    Enrollment change
    |
    cyclophosphamide • fludarabine IV • NKX019
    7ms
    IL2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL15. (PubMed, Mol Ther)
    cytoTIL15™ cells express mbIL15 fused to a drug-responsive domain (DRD) that is regulated by the FDA-approved small-molecule drug acetazolamide (ACZ). In patient-derived xenograft (PDX) tumors, spatial profiling revealed infiltrating cytoTIL15 cells to be highly cytotoxic and less exhausted than non-engineered TIL. This novel platform creates a powerful, IL2-free TIL cell therapy with a potentially improved tolerability and safety profile, while allowing individualized pharmacologic regulation of the TIL product.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • IL15 (Interleukin 15)
    |
    OBX-115 • acetazolamide
    8ms
    ELiPSE-1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Century Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=75 --> 28
    Enrollment closed • Enrollment change
    |
    CD19 positive
    |
    CNTY-101
    8ms
    VG201-C101: A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Virogin Biotech Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    VG201
    11ms
    A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC (clinicaltrials.gov)
    P1, N=152, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | N=108 --> 152
    Enrollment change
    |
    SIM0237
    11ms
    A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=78, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Oct 2024 --> Dec 2024
    Enrollment open • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    IAP0971